Published in Xenobiotica on September 05, 2011
Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance. Eur J Pharm Sci (2016) 0.76
Quantifying and Communicating Uncertainty in Preclinical Human Dose-Prediction. CPT Pharmacometrics Syst Pharmacol (2015) 0.75
Physiological parameters in laboratory animals and humans. Pharm Res (1993) 8.14
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol (2001) 4.97
Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci (2004) 4.28
Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health (1997) 3.48
Body size and metabolic rate. Physiol Rev (1947) 3.27
Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. Antimicrob Agents Chemother (1983) 2.58
Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm (1982) 2.10
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol (2005) 1.99
Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother (2005) 1.98
A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta (1999) 1.92
Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther (1999) 1.88
The 3/4 mass exponent for energy metabolism is not a statistical artifact. Respir Physiol (1983) 1.74
What's fueling the biotech engine? Nat Biotechnol (2007) 1.62
Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol (2003) 1.57
Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab Dispos (2003) 1.57
Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol (2006) 1.52
A comprehensive analysis of the role of correction factors in the allometric predictivity of clearance from rat, dog, and monkey to humans. J Pharm Sci (2004) 1.46
Pharmacokinetics of cefpiramide (SM-1652) in humans. Antimicrob Agents Chemother (1984) 1.43
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol (2009) 1.34
Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood (2008) 1.30
Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs (2007) 1.30
Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr Opin Investig Drugs (2001) 1.29
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos (2008) 1.29
Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos (2006) 1.27
Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res (2007) 1.27
The disposition and metabolism of meropenem in laboratory animals and man. J Antimicrob Chemother (1989) 1.25
Pharmacokinetic aspects of biotechnology products. J Pharm Sci (2004) 1.25
Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods (2009) 1.23
Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther (1991) 1.22
Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol (2004) 1.22
Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans. Drug Metab Dispos (1988) 1.21
Interspecies scaling of therapeutic monoclonal antibodies: initial look. J Clin Pharmacol (2009) 1.15
Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res (1991) 1.14
Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited. Biopharm Drug Dispos (2010) 1.14
Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin Cancer Res (2010) 1.13
Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. Clin Cancer Res (2004) 1.13
Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther (2005) 1.13
Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm (1999) 1.13
The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs (2008) 1.10
Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin. Drug Metab Dispos (2007) 1.09
Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol (2001) 1.08
Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica (1996) 1.07
First-time-in-human dose selection: allometric thoughts and perspectives. J Clin Pharmacol (1995) 1.07
Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers. J Antimicrob Chemother (1988) 1.06
Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. Life Sci (1986) 1.06
Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol (2007) 1.05
A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. Drug Metab Dispos (2004) 1.04
Preliminary pharmacokinetic model for adriamycin (NSC-123127). Cancer Chemother Rep (1975) 1.02
Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J Pharmacol Exp Ther (2002) 1.02
Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother Rep (1970) 1.01
Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons. Pharm Res (2010) 1.01
Pharmacokinetic allometric scaling of antibodies: application to the first-in-human dose estimation. J Pharm Sci (2009) 0.99
A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology (1999) 0.99
Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther (1990) 0.99
Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies. Curr Drug Metab (2009) 0.98
Comparative pharmacokinetics of nicardipine hydrochloride, a new vasodilator, in various species. Xenobiotica (1980) 0.97
Interspecies scaling of protein drugs: prediction of clearance from animals to humans. J Pharm Sci (2004) 0.97
Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet (2002) 0.96
Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine (ARA-C) deamination in several species. Biochem Pharmacol (1973) 0.95
Clinical evaluation of recombinant factor IX. Semin Hematol (1998) 0.95
Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. Br J Clin Pharmacol (2004) 0.94
Pharmacokinetics, renal clearance and metabolism of ciprofloxacin following intravenous and oral administration to calves and pigs. Vet Q (1988) 0.94
Modeling and allometric scaling of s(+)-ketoprofen pharmacokinetics and pharmacodynamics: a retrospective analysis. J Vet Pharmacol Ther (2004) 0.93
Application of fixed exponent 0.75 to the prediction of human drug clearance: an inaccurate and misleading concept. Drug Metabol Drug Interact (2009) 0.93
Allometric scaling of xenobiotic clearance: uncertainty versus universality. AAPS PharmSci (2001) 0.91
Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity. Clin Pharmacokinet (1995) 0.90
Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J Pharmacol Exp Ther (1996) 0.89
The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers. J Infect Dis (1996) 0.89
Pharmacokinetics and interspecies scaling of recombinant human factor VIII. Toxicol Appl Pharmacol (1996) 0.89
Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. J Pharm Sci (1997) 0.88
Elucidation of human amphotericin B pharmacokinetics: identification of a new potential factor affecting interspecies pharmacokinetic scaling. Pharm Res (1998) 0.88
Pharmacokinetics of an emerging new class of anticoagulant/antithrombotic drugs. A review of small-molecule thrombin inhibitors. Eur J Clin Pharmacol (2002) 0.87
Species differences in biotransformation and excretion of salicylate. Am J Vet Res (1972) 0.87
Pharmacokinetics and leukocyte responses of recombinant human interleukin-10. Pharm Res (1998) 0.87
Interspecies pharmacokinetic scaling of a new carbapenem, DA-1131, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics. Biopharm Drug Dispos (1998) 0.87
Clearance of fentanyl, alfentanil, methohexitone, thiopentone and ketamine in relation to estimated hepatic blood flow in several animal species: application to prediction of clearance in man. J Pharm Pharmacol (2000) 0.87
Pharmacokinetics of three commercial antivenoms in patients envenomed by the Malayan pit viper, Calloselasma rhodostoma, in Thailand. Am J Trop Med Hyg (1990) 0.87
Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19. Drug Metab Dispos (1995) 0.86
Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys. Thromb Haemost (2002) 0.85
Interspecies scaling of clearance and volume of distribution for horse antivenom F(ab')2. Toxicol Appl Pharmacol (1998) 0.84
Nonlinear pharmacokinetics of a recombinant human granulocyte colony-stimulating factor derivative (nartograstim): species differences among rats, monkeys and humans. J Pharmacol Exp Ther (1994) 0.84
Animal pharmacokinetics of the tumor necrosis factor receptor-immunoglobulin fusion protein lenercept and their extrapolation to humans. Drug Metab Dispos (1999) 0.84
Pharmacokinetics and pharmacodynamics of CTLA4lg (BMS-188667), a novel immunosuppressive agent, in monkeys following multiple doses. J Pharm Sci (1996) 0.83
Interspecies scaling of renally secreted drugs. Life Sci (1998) 0.83
The pharmacokinetics and organ distribution of ajmaline and quindine in the mouse. Naunyn Schmiedebergs Arch Pharmacol (1977) 0.83
Comparative drug metabolism. Prog Drug Res (1969) 0.83
Effect of aging on the pharmcokinetics of atenolol, metoprolol and propranolol in the rat. J Pharmacol Exp Ther (1990) 0.83
Kinetics of subcutaneous versus intravenous epoetin-beta in dogs, rats and mice. Pharmacology (1996) 0.83
Pharmacokinetics of ciprofloxacin. 2nd communication: distribution to and elimination from tissues and organs following single or repeated administration of [14C]ciprofloxacin in albino rats. Arzneimittelforschung (1986) 0.82
Prediction of the pharmacokinetics of cefodizime and cefotetan in humans from pharmacokinetic parameters in animals. J Pharmacobiodyn (1990) 0.82
Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator bm 06.022 in healthy volunteers. Thromb Haemost (1991) 0.82
Disposition and dynamics of atrial natriuretic factor in conscious rabbits. J Pharmacol Exp Ther (1989) 0.81
Comparative pharmacokinetics and interspecies scaling of amphotericin B in several mammalian species. J Pharm Pharmacol (1997) 0.81
Pharmacokinetics and clinical use of drotrecogin alfa (activated) in patients with severe sepsis. Pharmacotherapy (2002) 0.81
Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab. Toxicol Appl Pharmacol (1996) 0.80
Cyclosporine pharmacokinetics in rats and interspecies comparison in dogs, rabbits, rats, and humans. Drug Metab Dispos (1989) 0.80
Estimation of human drug clearance using multiexponential techniques. J Clin Pharmacol (2008) 0.80
Pharmacokinetics of GLQ223 in rats, monkeys, and patients with AIDS or AIDS-related complex. Antimicrob Agents Chemother (1991) 0.80
The status of the world's land and marine mammals: diversity, threat, and knowledge. Science (2008) 8.03
The crust of the Moon as seen by GRAIL. Science (2012) 2.63
Gravity field of the Moon from the Gravity Recovery and Interior Laboratory (GRAIL) mission. Science (2012) 2.17
The process addictions and the new ASAM definition of addiction. J Psychoactive Drugs (2012) 1.82
Mouse endogenous retroviruses can trigger premature transcriptional termination at a distance. Genome Res (2012) 1.81
The origin of lunar mascon basins. Science (2013) 1.67
Anesthesiologists and substance use disorders. Anesth Analg (2014) 1.38
Topography of the northern hemisphere of Mercury from MESSENGER laser altimetry. Science (2012) 1.38
Ancient igneous intrusions and early expansion of the Moon revealed by GRAIL gravity gradiometry. Science (2012) 1.37
Global distribution of large lunar craters: implications for resurfacing and impactor populations. Science (2010) 1.28
Targeted disruption of peptide transporter Pept1 gene in mice significantly reduces dipeptide absorption in intestine. Mol Pharm (2009) 1.28
Clathrin- and dynamin-dependent endocytic pathway regulates muramyl dipeptide internalization and NOD2 activation. J Immunol (2009) 1.26
Role and relevance of peptide transporter 2 (PEPT2) in the kidney and choroid plexus: in vivo studies with glycylsarcosine in wild-type and PEPT2 knockout mice. J Pharmacol Exp Ther (2005) 1.19
Impact of genetic knockout of PEPT2 on cefadroxil pharmacokinetics, renal tubular reabsorption, and brain penetration in mice. Drug Metab Dispos (2007) 1.19
Thermal stability of volatiles in the north polar region of Mercury. Science (2012) 1.14
Significance and regional dependency of peptide transporter (PEPT) 1 in the intestinal permeability of glycylsarcosine: in situ single-pass perfusion studies in wild-type and Pept1 knockout mice. Drug Metab Dispos (2010) 1.14
Immunolocalization of the proton-coupled oligopeptide transporter PEPT2 in developing rat brain. Mol Pharm (2005) 1.12
Peptide transporter 2 (PEPT2) expression in brain protects against 5-aminolevulinic acid neurotoxicity. J Neurochem (2007) 1.11
Targeted disruption of the PEPT2 gene markedly reduces dipeptide uptake in choroid plexus. J Biol Chem (2002) 1.10
Bright and dark polar deposits on Mercury: evidence for surface volatiles. Science (2012) 1.10
Role of PEPT2 in peptide/mimetic trafficking at the blood-cerebrospinal fluid barrier: studies in rat choroid plexus epithelial cells in primary culture. J Pharmacol Exp Ther (2002) 1.00
Carnosine uptake in rat choroid plexus primary cell cultures and choroid plexus whole tissue from PEPT2 null mice. J Neurochem (2004) 0.98
PEPT2 (Slc15a2)-mediated unidirectional transport of cefadroxil from cerebrospinal fluid into choroid plexus. J Pharmacol Exp Ther (2005) 0.97
Influence of genetic knockout of Pept2 on the in vivo disposition of endogenous and exogenous carnosine in wild-type and Pept2 null mice. Am J Physiol Regul Integr Comp Physiol (2009) 0.95
Role and relevance of PEPT2 in drug disposition, dynamics, and toxicity. Drug Metab Pharmacokinet (2008) 0.95
Enhanced antinociceptive response to intracerebroventricular kyotorphin in Pept2 null mice. J Neurochem (2009) 0.92
Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice. Drug Metab Dispos (2012) 0.92
Influence of fed-fasted state on intestinal PEPT1 expression and in vivo pharmacokinetics of glycylsarcosine in wild-type and Pept1 knockout mice. Pharm Res (2011) 0.92
Effect of dose escalation on the in vivo oral absorption and disposition of glycylsarcosine in wild-type and Pept1 knockout mice. Drug Metab Dispos (2011) 0.90
Preliminary investigation into the expression of proton-coupled oligopeptide transporters in neural retina and retinal pigment epithelium (RPE): lack of functional activity in RPE plasma membranes. Pharm Res (2003) 0.90
Impact of peptide transporter 1 on the intestinal absorption and pharmacokinetics of valacyclovir after oral dose escalation in wild-type and PepT1 knockout mice. Drug Metab Dispos (2013) 0.89
Buprenorphine in the treatment of opiate dependence. J Psychoactive Drugs (2010) 0.88
Relevance of PepT1 in the intestinal permeability and oral absorption of cefadroxil. Pharm Res (2012) 0.88
Mechanisms of cefadroxil uptake in the choroid plexus: studies in wild-type and PEPT2 knockout mice. J Pharmacol Exp Ther (2003) 0.87
New perspectives on ancient Mars. Science (2005) 0.86
In vivo absorption and disposition of cefadroxil after escalating oral doses in wild-type and PepT1 knockout mice. Pharm Res (2013) 0.85
Choroid plexus transport: gene deletion studies. Fluids Barriers CNS (2011) 0.85
Role of PEPT2 in glycylsarcosine transport in astrocyte and glioma cultures. Neurosci Lett (2005) 0.85
A phase I clinical and pharmacology study using amifostine as a radioprotector in dose-escalated whole liver radiation therapy. Int J Radiat Oncol Biol Phys (2012) 0.85
PEPT2-mediated transport of 5-aminolevulinic acid and carnosine in astrocytes. Brain Res (2006) 0.85
Free energy, energy, and entropy of swelling in Cs-, Na-, and Sr-montmorillonite clays. J Chem Phys (2004) 0.84
Asymmetric distribution of lunar impact basins caused by variations in target properties. Science (2013) 0.84
Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial. BMC Psychiatry (2005) 0.84
Can drug design inhibit abuse? J Psychoactive Drugs (2005) 0.83
Transport mechanisms of carnosine in SKPT cells: contribution of apical and basolateral membrane transporters. Pharm Res (2008) 0.83
Divergent developmental expression and function of the proton-coupled oligopeptide transporters PepT2 and PhT1 in regional brain slices of mouse and rat. J Neurochem (2014) 0.83
Glycyl-L-glutamine disposition in rat choroid plexus epithelial cells in primary culture: role of PEPT2. Pharm Res (2005) 0.83
PEPT1 enhances the uptake of gabapentin via trans-stimulation of b0,+ exchange. Pharm Res (2006) 0.83
Role of PEPT2 in the choroid plexus uptake of glycylsarcosine and 5-aminolevulinic acid: studies in wild-type and null mice. Pharm Res (2004) 0.83
Prescription stimulant sales on the Internet. Pediatr Ann (2006) 0.82
Effects of organic anion, organic cation, and dipeptide transport inhibitors on cefdinir in the isolated perfused rat kidney. Antimicrob Agents Chemother (2003) 0.81
Peptide transporter 1 is responsible for intestinal uptake of the dipeptide glycylsarcosine: studies in everted jejunal rings from wild-type and Pept1 null mice. J Pharm Sci (2010) 0.81
Species-dependent uptake of glycylsarcosine but not oseltamivir in Pichia pastoris expressing the rat, mouse, and human intestinal peptide transporter PEPT1. Drug Metab Dispos (2012) 0.81
Determination of WR-1065 in human blood by high-performance liquid chromatography following fluorescent derivatization by a maleimide reagent ThioGlo3. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 0.80
Functional and molecular expression of the proton-coupled oligopeptide transporters in spleen and macrophages from mouse and human. Mol Pharm (2013) 0.80
Density of Mars' south polar layered deposits. Science (2007) 0.80
A flexible, open, decentralized system for digital pathology networks. Stud Health Technol Inform (2012) 0.80
Development and characterization of a novel mouse line humanized for the intestinal peptide transporter PEPT1. Mol Pharm (2014) 0.79
Effect of diabetes mellitus and insulin on the regulation of the PepT 1 symporter in rat jejunum. Mol Pharm (2005) 0.79
Kyotorphin transport and metabolism in rat and mouse neonatal astrocytes. Brain Res (2010) 0.79
Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. Drug Metab Dispos (2012) 0.78
Regional pharmacokinetics of amifostine in anesthetized dogs: role of the liver, gastrointestinal tract, lungs, and kidneys. Drug Metab Dispos (2002) 0.78
Impact of lipopolysaccharide-induced inflammation on the disposition of the aminocephalosporin cefadroxil. Antimicrob Agents Chemother (2013) 0.78
Pharmacodynamic differentiation of lorazepam sleepiness and dizziness using an ordered categorical measure. J Pharm Sci (2010) 0.78
Identification and characterization of mechanistically distinct inducers of gamma-globin transcription. Biochem Pharmacol (2003) 0.78
[Osteosarcoma lung metastases. Survival after chemotherapy and surgery]. Medicina (B Aires) (2015) 0.78
Population pharmacokinetics of mycophenolic acid in lung transplant recipients with and without cystic fibrosis. Eur J Clin Pharmacol (2015) 0.77
[11C]Glycylsarcosine: synthesis and in vivo evaluation as a PET tracer of PepT2 transporter function in kidney of PepT2 null and wild-type mice. Bioorg Med Chem (2005) 0.77
Integration of pharmacotherapy and psychosocial treatment in opiate-addicted youth. J Psychoactive Drugs (2011) 0.77
Importance of Peptide transporter 2 on the cerebrospinal fluid efflux kinetics of glycylsarcosine characterized by nonlinear mixed effects modeling. Pharm Res (2013) 0.77
From Hofmann to the Haight Ashbury, and into the future: the past and potential of lysergic acid diethlyamide. J Psychoactive Drugs (2014) 0.77
The medicalization of therapeutic communities in the era of health care reform. J Psychoactive Drugs (2012) 0.76
Neurogenetic and epigenetic correlates of adolescent predisposition to and risk for addictive behaviors as a function of prefrontal cortex dysregulation. J Child Adolesc Psychopharmacol (2015) 0.76
Impact of intestinal PepT1 on the kinetics and dynamics of N-formyl-methionyl-leucyl-phenylalanine, a bacterially-produced chemotactic peptide. Mol Pharm (2013) 0.76
Expression and regulation of the proton-coupled oligopeptide transporter PhT2 by LPS in macrophages and mouse spleen. Mol Pharm (2014) 0.75
Water-refined solution structure of the human Grb7-SH2 domain in complex with the erbB2 receptor peptide pY1139. Protein Pept Lett (2012) 0.75
Constraints on the volatile distribution within Shackleton crater at the lunar south pole. Nature (2012) 0.75
Journal of Psychoactive Drugs. A multidisciplinary forum. J Psychoactive Drugs (2008) 0.75
Disposition of WR-1065 in the liver of tumor-bearing rats following regional vs systemic administration of amifostine. Biopharm Drug Dispos (2004) 0.75
What proportion of sexually transmissible infections and HIV are diagnosed in New South Wales' public sexual health services compared with other services? Sex Health (2013) 0.75
The evolution of addiction medicine and its San Francisco roots. J Psychoactive Drugs (2010) 0.75
Free space laser communication experiments from Earth to the Lunar Reconnaissance Orbiter in lunar orbit. Opt Express (2013) 0.75
Arrhythmogenic right ventricular cardiomyopathy/dysplasia: a case report of identical twins with heart failure. Pacing Clin Electrophysiol (2002) 0.75
Functional characterization of human peptide/histidine transporter 1 in stably transfected MDCK cells. Mol Pharm (2017) 0.75
Laser altimeter observations from MESSENGER's first Mercury flyby. Science (2008) 0.75
In vivo effects of glycyl-glutamate and glycyl-sarcosine on gabapentin oral absorption in rat. Pharm Res (2007) 0.75
Addiction and related disorders. J Psychoactive Drugs (2010) 0.75
The doctor's dilemma. Med J Aust (2007) 0.75
Effectiveness of a locking plate in preserving midcalcaneal length and positional outcome after Evans calcaneal osteotomy: a retrospective pilot study. J Foot Ankle Surg (2013) 0.75